Evogene Ltd. CTO Mark Kapel to Depart
Ticker: EVGN · Form: 6-K · Filed: Sep 17, 2024 · CIK: 1574565
Sentiment: neutral
Topics: management-change, restructuring
TL;DR
Evogene's CTO is out Oct 31st as part of a restructure.
AI Summary
Evogene Ltd. announced on September 17, 2024, that Chief Technology Officer Mark Kapel will leave the company effective October 31, 2024, as part of an organizational restructuring. The company expressed gratitude for his contributions.
Why It Matters
Changes in key management personnel can signal shifts in company strategy or operational focus, potentially impacting future performance.
Risk Assessment
Risk Level: low — This filing is a routine report of a management change and does not involve financial transactions or significant operational updates.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Mark Kapel (person) — Chief Technology Officer
FAQ
What is the effective date of Mark Kapel's departure?
Mark Kapel's employment with Evogene will conclude effective October 31, 2024.
What is Mark Kapel's role at Evogene?
Mark Kapel is the Company's Chief Technology Officer.
Why is Mark Kapel leaving Evogene?
He is leaving as part of an organizational restructuring.
What is the filing date of this report?
This report was filed on September 17, 2024.
What form is Evogene Ltd. filing?
Evogene Ltd. is filing a Form 6-K.
Filing Stats: 366 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-09-17 07:00:12
Filing Documents
- zk2432045.htm (6-K) — 10KB
- 0001178913-24-003081.txt ( ) — 11KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd., or Evogene, reports changes in its management team: As part of an organizational restructuring, Mr. Mark Kapel, the Company's Chief Technology Officer, will conclude his employment with Evogene, effective October 31, 2024. Evogene expresses its gratitude to Mr. Kapel for his contributions during his tenure. Mr. Kapel will continue to provide consulting services to Evogene. The Chief Technology Officer's responsibilities will be divided between the Evogene's VP Computational Platform, Dr. Ilia Zhidkov, and the VP Experimental Research Center, Dr. Silvia Shaked, both of whom have been with Evogene for the past 13 years. In addition, Dr. Gabi Tarcic, will be appointed as Evogene's VP Product, effective September 22, 2024. Dr. Tarcic has extensive experience in research and development projects and as a senior executive. Since 2012 Dr. Tarcic has served in various positions at Fore Biotherapeutics (formerly NovellusDx Israel), most recently as its Chief Technology Officer. Dr. Tarcic holds a Ph.D. from The Weizmann Institute of Science, Rehovot, Israel. This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 17, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer